• 1
    Berrino F, De Angelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 77383.
  • 2
    Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009; 10: 8895.
  • 3
    Thompson CC, Ashcroft FJ, Patel S et al. Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 2007; 56: 95106.
  • 4
    Nomura H, Uzawa K, Ishigami T et al. Clinical significance of gelsolin-like actin-capping protein expression in oral carcinogenesis: an immunohistochemical study of premalignant and malignant lesions of the oral cavity. BMC Cancer 2008; 8: 39.
  • 5
    Shapland C, Lowings P, Lawson D. Identification of new actin-associated polypeptides that are modified by viral transformation and changes in cell shape. J Cell Biol 1988; 107: 15361.
  • 6
    Lawson D, Harrison M, Shapland C. Fibroblast transgelin and smooth muscle SM22alpha are the same protein, the expression of which is down-regulated in many cell lines. Cell Motil Cytoskeleton 1997; 38: 2507.
  • 7
    Gimona M, Kaverina I, Resch GP, Vignal E, Burgstaller G. Calponin repeats regulate actin filament stability and formation of podosomes in smooth muscle cells. Mol Biol Cell 2003; 14: 248291.
  • 8
    Assinder SJ, Stanton JA, Prasad PD. Transgelin: an actin-binding protein and tumour suppressor. Int J Biochem Cell Biol 2009; 41: 4826.
  • 9
    Prasad PD, Stanton JA, Assinder SJ. Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer. Cell Tissue Res 2010; 339: 33747.
  • 10
    Zhao L, Wang H, Deng YJ et al. Transgelin as a suppressor is associated with poor prognosis in colorectal carcinoma patients. Mod Pathol 2009; 22: 78696.
  • 11
    Qi Y, Chiu JF, Wang L, Kwong DL, He QY. Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics 2005; 5: 296071.
  • 12
    Yeo M, Park HJ, Kim DK et al. Loss of SM22 is a characteristic signature of colon carcinogenesis and its restoration suppresses colon tumorigenicity in vivo and in vitro. Cancer 2010; 116: 25819.
  • 13
    Yang Z, Chang YJ, Miyamoto H et al. Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol Endocrinol 2007; 21: 34358.
  • 14
    Huang Q, Huang Q, Chen W et al. Identification of transgelin as a potential novel biomarker for gastric adenocarcinoma based on proteomics technology. J Cancer Res Clin Oncol 2008; 134: 121927.
  • 15
    Lin Y, Buckhaults PJ, Lee JR et al. Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer. Neoplasia 2009; 11: 86473.
  • 16
    Mikuriya K, Kuramitsu Y, Ryozawa S et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 2007; 30: 84955.
  • 17
    Tian R, Wei LM, Qin RY et al. Proteome analysis of human pancreatic ductal adenocarcinoma tissue using two-dimensional gel electrophoresis and tandem mass spectrometry for identification of disease-related proteins. Dig Dis Sci 2008; 53: 6572.
  • 18
    Lu Z, Hu L, Evers S, Chen J, Shen Y. Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics 2004; 4: 397588.
  • 19
    Gavin JR 3rd, Davidson MB, Defronzo RA et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 (Suppl 1): S520.
  • 20
    Wang Z, Jiang L, Huang C et al. Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol Cell Proteomics 2008; 7: 163950.
  • 21
    Zhou L, Zhang R, Wang L et al. Upregulation of REG Ialpha accelerates tumor progression in pancreatic cancer with diabetes. Int J Cancer 2010; 127: 1795803.
  • 22
    Koong AC, Mehta VK, Le QT et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000; 48: 91922.
  • 23
    Duffy JP, Eibl G, Reber HA, Hines OJ. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer 2003; 2: 12.
  • 24
    Vaupel P, Thews O, Kelleher DK. Pancreatic tumors show high levels of hypoxia: regarding Koong et al. IJROBP 2000; 48: 919–922. Int J Radiat Oncol Biol Phys 2001; 50: 1099100.
  • 25
    Zhang R, Zhou L, Li Q, Liu J, Yao W, Wan H. Up-regulation of two actin-associated proteins prompts pulmonary artery smooth muscle cell migration under hypoxia. Am J Respir Cell Mol Biol 2009; 41: 46775.
  • 26
    Kim TR, Cho EW, Paik SG, Kim IG. Hypoxia-induced SM22alpha in A549 cells activates the IGF1R/PI3K/Akt pathway, conferring cellular resistance against chemo- and radiation therapy. FEBS Lett 2012; 586: 3039.
  • 27
    Wykoff CC, Sotiriou C, Cockman ME et al. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer 2004; 90: 123543.
  • 28
    Ryu JW, Kim HJ, Lee YS et al. The proteomics approach to find biomarkers in gastric cancer. J Korean Med Sci 2003; 18: 5059.
  • 29
    Shields JM, Rogers-Graham K, Der CJ. Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem 2002; 277: 97909.
  • 30
    Je HD, Sohn UD. SM22alpha is required for agonist-induced regulation of contractility: evidence from SM22alpha knockout mice. Mol Cells 2007; 23: 17581.
  • 31
    Yu H, Konigshoff M, Jayachandran A et al. Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis. FASEB J 2008; 22: 177889.
  • 32
    Lien SC, Usami S, Chien S, Chiu JJ. Phosphatidylinositol 3-kinase/Akt pathway is involved in transforming growth factor-beta1-induced phenotypic modulation of 10T1/2 cells to smooth muscle cells. Cell Signal 2006; 18: 12708.
  • 33
    Qiu P, Feng XH, Li L. Interaction of Smad3 and SRF-associated complex mediates TGF-beta1 signals to regulate SM22 transcription during myofibroblast differentiation. J Mol Cell Cardiol 2003; 35: 140720.
  • 34
    Qiu P, Ritchie RP, Fu Z et al. Myocardin enhances Smad3-mediated transforming growth factor-beta1 signaling in a CArG box-independent manner: Smad-binding element is an important cis element for SM22alpha transcription in vivo. Circ Res 2005; 97: 98391.
  • 35
    Qiu P, Ritchie RP, Gong XQ, Hamamori Y, Li L. Dynamic changes in chromatin acetylation and the expression of histone acetyltransferases and histone deacetylases regulate the SM22alpha transcription in response to Smad3-mediated TGFbeta1 signaling. Biochem Biophys Res Commun 2006; 348: 3518.
  • 36
    Rahimi RA, Leof EB. TGF-beta signaling: a tale of two responses. J Cell Biochem 2007; 102: 593608.
  • 37
    Achyut BR, Yang L. Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 2011; 141: 116778.
  • 38
    Lu Z, Friess H, Graber HU et al. Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage. Dig Dis Sci 1997; 42: 205463.
  • 39
    Sitek B, Luttges J, Marcus K et al. Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. Proteomics 2005; 5: 266579.
  • 40
    Chari ST, Leibson CL, Rabe KG et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134: 95101.
  • 41
    Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci U S A 2000; 97: 76679.
  • 42
    Sundsten T, Ortsater H. Proteomics in diabetes research. Mol Cell Endocrinol 2009; 297: 93103.
  • 43
    Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 240313.
  • 44
    Rothenberg ML, Moore MJ, Cripps MC et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 34753.
  • 45
    Lee EK, Han GY, Park HW, Song YJ, Kim CW. Transgelin promotes migration and invasion of cancer stem cells. J Proteome Res 2010; 9: 510817.